Mereo BioPharma Group Balance Sheet Health
Financial Health criteria checks 6/6
Mereo BioPharma Group has a total shareholder equity of $42.8M and total debt of $4.6M, which brings its debt-to-equity ratio to 10.8%. Its total assets and total liabilities are $55.9M and $13.1M respectively.
Key information
10.8%
Debt to equity ratio
US$4.63m
Debt
Interest coverage ratio | n/a |
Cash | US$48.66m |
Equity | US$42.84m |
Total liabilities | US$13.10m |
Total assets | US$55.94m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0A9G's short term assets ($53.5M) exceed its short term liabilities ($11.0M).
Long Term Liabilities: 0A9G's short term assets ($53.5M) exceed its long term liabilities ($2.1M).
Debt to Equity History and Analysis
Debt Level: 0A9G has more cash than its total debt.
Reducing Debt: 0A9G's debt to equity ratio has reduced from 33.4% to 10.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0A9G has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0A9G has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 8.5% each year.